enzym
play
import
role
sever
biolog
process
includ
digest
absorpt
metabol
propag
function
essenti
live
organ
close
associ
mani
pathogen
mechan
enzym
inhibitor
activ
therefor
repres
import
molecular
target
develop
new
diseas
treatment
among
enzym
proteas
import
molecular
target
substrat
protein
proteas
peptid
play
crucial
role
form
virus
human
proteas
categor
four
major
class
aspart
proteas
serin
proteas
cystein
proteas
metalloproteas
contain
aspart
acid
serin
cystein
metal
ion
respect
activ
site
renin
first
proteas
inhibitor
design
logic
use
comput
approach
drug
design
sbdd
renin
aspart
proteas
involv
first
step
system
raa
molecular
target
antihypertens
renin
cleav
angiotensinogen
releas
decapeptid
angiotensin
shown
figur
angiotensin
subsequ
cleav
nonspecif
dipeptidyl
carboxypeptidas
enzym
ace
releas
potent
octapeptid
vasopressor
angiotensin
ii
pepsin
inhibitor
pepstatin
featur
acid
statin
transit
state
analogu
report
inhibit
activ
renin
sinc
mani
renin
inhibitor
contain
transit
state
analogu
boger
et
al
design
renin
inhibitor
call
renin
inhibitori
peptid
scrip
inhibitori
concentr
nm
figur
statin
residu
posit
contain
part
angiotensinogen
amino
acid
also
design
synthes
potent
small
inhibitor
nm
contain
residu
transit
state
first
renin
inhibitor
drug
aliskiren
nm
novarti
speedel
approv
us
food
drug
administr
fda
aspart
proteas
form
substrat
transit
state
coval
bond
substrat
proteas
discuss
later
result
inhibitor
easili
design
use
comput
approach
develop
inhibitor
metalloproteas
ace
wait
discoveri
peptid
figur
found
venom
snake
bothrop
jararaca
inhibit
ace
first
ace
inhibitor
drug
captopril
approv
fda
design
emul
sequenc
prolin
residu
captopril
dock
pocket
ace
anoth
residu
dock
pocket
coordin
bond
form
sulfur
atom
captopril
zinc
ion
activ
site
ace
appear
contribut
potent
inhibit
subsequ
human
immunodefici
viru
type
proteas
inhibitor
design
use
comput
approach
develop
therapeut
treatment
acquir
immunodefici
syndrom
aid
proteas
also
aspart
proteas
inhibitor
design
use
approach
similar
use
design
renin
inhibitor
proteas
respons
process
gag
polyprotein
enabl
prolifer
retroviru
first
proteas
inhibitor
approv
fda
saquinavir
figur
develop
use
comput
approach
mani
proteas
inhibitor
ie
saquinavir
indinavir
nelfinavir
atazanavir
darunavir
possess
hydroxyethylamin
moieti
act
transit
state
analogu
wherea
ritonavir
lopinavir
possess
hydroxyethylen
moieti
transit
state
analogu
use
proteas
inhibitor
highli
activ
antiretrovir
therapi
haart
contribut
consider
overcom
proteas
inhibitor
hydroxyl
group
transit
state
analogu
residu
strongli
bind
activ
site
proteas
also
report
seri
potent
proteas
inhibitor
contain
residu
allophenylnorstatin
apn
transit
state
analogu
figur
furthermor
use
transit
state
concept
design
inhibitor
sever
aspart
proteas
malari
plasmepsin
human
viru
type
describ
latest
develop
proteas
inhibitor
design
includ
work
aspart
proteas
two
catalyt
aspart
acid
residu
activ
site
first
water
molecul
deproton
carboxyl
anion
one
aspart
acid
side
chain
result
hydroxid
ion
attack
carbonyl
carbon
substrat
cleavag
site
form
tetrahedr
transit
state
shown
figur
rearrang
transit
state
caus
amid
bond
substrat
broken
although
serin
cystein
proteas
cleav
peptid
bond
via
transit
state
consist
coval
bond
catalyt
serinecystein
carbonyl
carbon
cleavag
posit
substrat
aspart
proteas
form
transit
state
base
noncoval
interact
carboxyl
acidcarboxyl
group
two
hydroxyl
group
substrat
fact
transit
state
aspart
proteas
involv
coval
bond
format
make
tetrahedr
structur
transit
state
rel
simpl
make
possibl
design
aspart
proteas
inhibitor
logic
use
comput
approach
malaria
diseas
caus
parasit
protozoa
genu
plasmodium
feed
haemoglobin
infect
person
protozoa
produc
famili
aspart
proteas
plasmepsin
degrad
host
haemoglobin
eventu
caus
symptom
malaria
death
host
plasmepsin
current
investig
molecular
target
antimalari
drug
plasmepsin
known
consist
least
ten
ii
iii
iv
v
vi
vii
ix
x
proteas
hap
encod
parasit
genom
although
plasmepsin
two
aspart
acid
moieti
catalyt
site
one
catalyt
aspart
acid
residu
replac
histidin
case
hap
among
plasmepsin
isoform
plm
plm
ii
known
readili
cleav
haemoglobin
residu
subunit
tabl
franci
et
al
report
figur
select
block
aspart
hemoglobinas
prevent
haemoglobin
degrad
kill
parasit
screen
peptidomimet
aspart
proteas
inhibitor
compound
ro
report
moon
ro
identifi
inhibitor
librari
inhibit
strain
p
silva
et
al
report
plasmepsin
inhibitor
screen
inhibitor
librari
aspart
proteas
catepsin
carrol
et
al
found
ps
combinatori
haqu
et
al
report
screen
catepsin
inhibitor
cleavag
site
plm
plm
ii
similar
proteas
shown
tabl
sever
potent
proteas
inhibitor
test
plasmepsin
proteas
inhibitor
shown
inhibit
plasmepsin
ii
inhibitori
constant
k
less
exhibit
highest
select
plasmepsin
ii
among
test
compound
addit
design
inhibitor
figur
incorpor
indan
deriv
posit
subunit
recogn
plm
plm
ii
ser
residu
predict
hydroxyl
group
indan
deriv
appear
mimic
hydroxyl
group
side
chain
inhibitor
assay
inhibitori
activ
four
main
plasmepsin
plm
plm
ii
plm
iv
although
show
potent
inhibitori
activ
plm
plm
ii
plm
iv
exhibit
low
inhibitori
activ
hap
molecul
abl
inhibit
enzymat
activ
four
main
plasmepsin
might
lead
rapid
starvat
parasit
could
effect
mutant
parasit
found
significantli
potent
could
effect
inhibit
four
main
plasmepsin
amyloid
peptid
main
compon
plaqu
brain
ad
patient
form
proteolysi
amyloid
precursor
protein
app
aspart
proteas
also
known
enzym
trigger
format
cleav
app
domain
figur
next
cleav
either
val
ile
ala
thr
residu
domain
form
either
respect
figur
show
greater
neurotox
aggreg
appear
key
biomolecular
marker
ad
pathogenesi
base
amyloid
hypothesi
mani
inhibitor
design
synthes
drug
candid
alzheim
fact
transgen
mice
live
normal
suggest
promis
molecular
target
ad
drug
inhibitor
possess
transit
state
analogu
posit
design
base
amino
acid
sequenc
swedish
mutant
app
doubl
mutat
around
residu
inhibit
swedish
mutat
app
import
increas
level
mani
app
mutat
ad
patient
report
mutat
acceler
level
aggreg
recent
mutat
report
mutat
identifi
set
sequenc
data
iceland
peopl
gene
low
risk
ad
protect
ad
declin
find
appear
verifi
valid
amyloid
hypothesi
ad
sinha
et
al
elan
pharmaceut
succeed
purifi
human
brain
use
inhibitor
statin
residu
substrat
transit
state
analogu
succeed
clone
sinc
mani
research
group
report
inhibitor
ghosh
et
al
report
potent
inhibitor
k
nm
k
nm
contain
hydroxyethylen
unit
substrat
transit
state
analogu
first
crystal
structur
complex
recombin
inhibitor
figur
report
octapeptid
inhibitor
nm
possess
hydroxymethylcarbonyl
hmc
isoster
substrat
transit
state
analogu
leu
residu
moreov
seri
small
potent
inhibitor
nm
nm
nm
develop
lead
compound
base
figur
carboxyl
group
replac
carboxyl
acid
bioisoster
tetrazol
ring
compound
found
potent
possess
group
posit
show
improv
inhibitori
activ
cultur
cell
stabli
express
human
first
nonpeptid
inhibitor
figur
report
research
takeda
chemic
industri
found
screen
chemic
librari
human
neuroblastoma
cell
line
vitro
fluoresc
reson
energi
transfer
fret
assay
use
recombin
human
competit
studi
inhibitor
indic
show
inhibit
noncompetit
manner
recent
fukumoto
takeda
chemic
industri
univers
tokyo
carri
surfac
plasmon
reson
spr
experi
show
bind
specif
region
portion
use
truncat
result
suggest
target
catalyt
site
domain
howev
inhibitor
subsequ
report
research
group
target
activ
site
elan
pharmaceut
report
seri
nonpeptid
inhibitor
nm
figur
possess
transit
state
analogu
design
use
sbdd
approach
compound
isophthal
residu
preferenti
arrang
planar
aromat
ring
site
form
cleft
flap
domain
narrow
mani
inhibitor
aromat
ring
posit
subsequ
report
exampl
research
group
merck
sharp
dohm
msd
report
potent
nm
respect
isophthal
pyridin
scaffold
respect
ghosh
et
al
report
potent
inhibitor
nm
featur
isophthal
research
novarti
report
nonpeptid
inhibitor
nm
although
design
base
peptidomimet
inhibitor
use
sbdd
approach
notabl
form
uniqu
cyclic
structur
posit
hydroxyl
amino
group
cyclic
sulfon
ring
appear
interact
two
asp
residu
activ
site
well
act
transit
state
analogu
use
high
throughput
screen
ht
approach
mani
inhibitor
design
wyeth
merg
pfizer
report
seri
inhibitor
base
ht
hit
potent
inhibitor
nm
base
ht
hit
compound
research
group
johnson
johnson
astex
therapeut
identifi
ht
compound
k
nm
chemic
librari
design
inhibitor
k
nm
recent
sever
clinic
trial
inhibitor
carri
eli
lilli
announc
inhibitor
termin
phase
ii
clinic
stage
abnorm
liver
biochem
test
result
howev
advers
event
caus
inhibitor
current
clinic
trial
report
yet
probabl
appear
uniqu
effect
recent
eli
lilli
astrazeneca
announc
collabor
partnership
phase
iiiii
trial
inhibitor
develop
although
termin
phase
clinic
stage
clinic
trial
latest
gener
inhibitor
complet
encourag
result
alzheim
patient
healthi
particip
effect
reduc
level
cerebrospin
fluid
also
design
nonpeptid
inhibitor
featur
transit
state
analogu
shown
figur
inhibitor
pyridinedicarboxyl
chelidon
scaffold
posit
base
virtual
inhibitor
isophthalamid
moieti
posit
design
use
silico
conform
sbdd
oxazolidin
ring
fix
turn
structur
phenyl
ring
posit
ring
ring
close
bind
quantum
interact
inhibitor
side
chain
play
import
role
inhibit
mechan
previous
specul
halogen
atom
could
bind
guanidin
quantum
interact
design
potent
inhibitor
halogen
atom
ring
adult
leukaemia
atl
associ
myelopathi
ham
caus
infect
retroviru
process
precursor
polyprotein
via
uniqu
aspart
proteas
proteas
sinc
proteas
similar
proteas
potent
proteas
inhibitor
compound
ritonavir
test
inhibitor
unfortun
compound
ineffect
therefor
design
proteas
inhibitor
use
substrat
transit
state
concept
well
develop
renin
proteas
inhibitor
shown
figur
octapeptid
inhibitor
nm
transit
state
analogu
design
base
substrat
gag
precursor
polyprotein
process
maca
cleavag
site
shown
figur
compound
exhibit
moder
potent
inhibitori
activ
proteas
insert
amino
acid
dimethylthiazolidin
dmt
prolin
bioisoster
small
hexapeptid
proteas
inhibitor
nm
respect
subsequ
hydrophob
branch
amino
acid
found
prefer
posit
potent
proteas
inhibitor
nm
possess
recent
reveal
first
crystal
structur
proteas
complex
crystal
structur
similar
proteas
complex
crystal
structur
expect
use
design
potent
proteas
inhibitor
drug
hepat
c
involv
sever
liver
inflamm
caus
rna
viru
hcv
interferon
hcv
rna
polymeras
inhibitor
cyclophilin
inhibitor
hcv
proteas
inhibitor
well
known
agent
among
proteas
serin
proteas
possess
serin
residu
activ
site
polyprotein
encod
hcv
rna
proteolyt
cleav
four
structur
protein
c
host
signal
peptidas
subsequ
six
nonstructur
ns
protein
releas
complex
respons
releas
four
nonstructur
protein
essenti
hcv
replic
first
hcv
proteas
inhibitor
telaprevir
figur
codevelop
vertex
pharmaceut
johnson
johnson
approv
treatment
hcv
infect
fda
telaprevir
consist
six
residu
correspond
posit
possess
group
posit
compound
boceprevir
also
possess
group
posit
develop
merg
msd
approv
fda
inhibitor
possess
group
would
design
bind
activ
site
enzym
via
coval
bond
carbonyl
carbon
group
oxygen
atom
side
chain
found
activ
site
crystal
structur
complex
pdb
id
shown
figur
expect
shown
inhibitor
carbonyl
carbon
bind
side
chain
via
coval
bond
carbonyl
carbon
form
tetrahedr
structur
like
amid
carbonyl
group
next
carbonyl
carbon
stabil
tetrahedr
structur
subsequ
noncoval
inhibitor
vaniprevir
danoprevir
simeprevir
report
squibb
msd
array
biopharma
medivirjohnson
johnson
respect
simeprevir
approv
fda
use
combin
ribavirin
inhibitor
possess
cyclopropanesulfonylamid
group
appear
bind
activ
site
enzym
via
hydrogen
bond
crystal
structur
complex
pdb
id
shown
one
oxygen
atom
sulfonyl
group
interact
catalyt
side
chain
amino
group
acid
sulfonyl
group
might
allow
tight
bind
inhibitor
hydrophil
activ
site
consist
side
chain
amino
group
biggest
problem
proteas
inhibitor
variant
emerg
rapidli
singl
administr
drug
henc
treatment
chronic
hepat
c
proteas
inhibitor
commonli
use
combin
pegyl
interferon
peginterferon
nucleosid
inhibitor
ribavirin
recent
squibb
develop
first
hepat
c
proteas
inhibitor
asunaprevir
replic
inhibitor
daclatasvir
dual
abbvi
also
develop
multipl
dose
regimen
consist
proteas
inhibitor
paritaprevir
ritonavir
combin
replic
inhibitor
ombitasvir
polymeras
inhibitor
dasabuvir
incretin
gastrointestin
hormon
increas
insulin
secret
respons
glucos
level
two
main
incretin
hormon
gastric
inhibitori
peptid
gip
also
known
insulinotrop
peptid
hormon
rapidli
cleav
inactiv
serin
proteas
inhibitor
expect
drug
candid
type
diabet
recogn
residu
peptid
lead
releas
dipeptid
sinc
also
recogn
sequenc
cleav
dipeptid
respect
residu
thought
exist
mani
proteinspeptid
inhibitor
predict
mani
side
effect
addit
known
dpp
famili
consist
nine
enzym
among
similar
structur
select
inde
lanka
et
al
report
toxic
inhibit
nonselect
rat
alopecia
thrombocytopenia
reticulocytopenia
enlarg
spleen
multiorgan
histopatholog
chang
mortal
dog
gastrointestin
inhibitor
use
antidiabet
drug
therefor
need
highli
specif
inhibitor
design
base
sequenc
substrat
first
inhibitor
sitagliptin
figur
develop
msd
approv
oral
antidiabet
drug
fda
sitagliptin
acid
unit
uniqu
cyclic
amin
correspond
phe
pro
residu
inhibitor
vidagliptin
anagliptin
alogliptin
possess
cyanopyrrolidin
group
correspond
pro
residu
develop
novalti
sanwa
kagaku
kenkyusho
takeda
pharmaceut
compani
anagliptin
approv
use
japan
cyanopyrrolidin
inhibitor
appar
design
base
coval
bond
format
inhibitor
catalyt
side
chain
enzym
howev
alogliptin
show
coval
bond
side
chain
crystal
structur
complex
enzym
pdb
id
shown
figur
cyano
group
interact
side
chain
enzym
catalyt
side
chain
interact
alogliptin
instead
bind
reli
dock
inhibitor
phenyl
ring
hydrophob
pocket
ionic
bond
inhibitor
amino
group
side
chain
stack
interact
inhibitor
quinazolinon
ring
side
chain
appear
allow
potent
bind
mode
linagliptin
develop
boehring
ingelheim
lilli
approv
fda
linagliptin
possess
cyano
group
amino
group
unsatur
alkyl
group
uracil
ring
linagliptin
interact
side
chain
pocket
side
chain
via
ionic
bond
hydrophob
interact
stack
respect
well
alogliptin
mani
proteas
inhibitor
develop
therapi
diseas
hypertens
aid
adult
leukaemia
malaria
alzheim
diseas
hepat
diabet
inhibitor
aspart
proteas
renin
proteas
malari
plasmepsin
proteas
design
use
transit
state
analogu
concept
unifi
design
concept
case
serin
cystein
proteas
effici
develop
inhibitor
proteas
new
design
concept
technolog
requir
despit
difficulti
mani
drug
develop
base
inhibit
metalloproteas
ace
serin
proteas
hcv
proteas
although
sever
acut
respiratori
syndrom
sar
coronaviru
main
proteas
mpro
discuss
review
articl
mpro
categor
cystein
potenti
treatment
futur
viral
epidem
develop
new
design
strategi
proteas
inhibitor
design
technolog
extrem
import
aspart
proteas
inhibitor
easili
design
use
comput
approach
dock
simul
silico
screen
silico
de
novo
design
aspart
proteas
form
tetrahedr
substrat
transit
state
rel
simpl
sinc
contain
coval
bond
enzym
substrat
hand
cysteineserin
proteas
form
coval
bond
substrat
transit
state
therefor
difficult
ration
design
transit
state
analogu
inhibitor
cysteineserin
proteas
use
dock
simul
van
der
waal
repuls
gener
inhibitor
catalyt
amino
acid
side
chain
case
metalloproteas
ace
inhibitor
develop
wait
discoveri
peptid
snake
venom
design
inhibitor
use
comput
approach
seem
imposs
case
serin
proteas
hepat
c
viru
proteas
inhibitor
develop
earli
stage
inhibitor
form
coval
bond
enzym
shown
figur
coval
inhibitor
keton
aldehyd
group
gener
unstabl
nucleophil
agent
enzym
vivo
next
noncoval
inhibitor
featur
cyclopropanesulfonylamid
group
report
although
inhibitor
sulfonyl
oxygen
atom
interact
catalyt
ser
side
chain
hydrogen
bond
shown
figur
attract
forc
weaker
transit
state
inhibitor
inhibitor
show
potent
inhibitori
activ
elong
direct
site
compound
cycliz
fix
conform
dock
activ
site
enzym
anoth
group
serin
proteas
proteas
inhibitor
design
anticip
coval
bond
form
inhibitor
cyano
carbon
catalyt
ser
side
chain
howev
crystal
structur
proteas
complex
show
coval
bond
enzym
inhibitor
shown
figur
mention
previous
difficult
ration
design
serin
cystein
proteas
base
pure
knowledg
amino
acid
sequenc
substrat
inhibitor
ace
hcv
proteas
develop
use
uniqu
design
concept
bind
catalyt
side
chain
enzym
uniqu
manner
contrast
aspart
proteas
inhibitor
design
logic
base
amino
acid
sequenc
substrat
mani
aspart
proteas
inhibitor
transit
state
analogu
posit
structur
simpl
recent
determin
whole
structur
complex
form
proteas
contain
locat
proton
shown
figur
although
proton
directli
observ
use
convent
crystallographi
success
determin
coordin
achiev
first
time
use
neuron
crystallographi
shown
figur
cleavag
mechan
aspart
proteas
carboxyl
acid
proton
carboxyl
anion
activ
site
enzym
interact
substrat
transit
state
via
two
hydrogen
bond
transit
state
analogu
interact
carboxyl
acid
proton
carboxyl
anion
manner
accur
mimic
substrat
transit
state
transit
state
analogu
inhibitor
allow
potent
inhibit
enzym
activ
transit
state
analogu
bind
strongli
activ
site
enzym
cleav
enzymat
